US Stock Market Movement | Bambusa Therapeutics (BBTX.US) Listed on US Market, Share Price Drops Over 8%

智通财经APP has learned that on Friday, Bambusa Therapeutics (BBTX.US) debuted on the US stock market. As of press time, the stock had fallen more than 8%, trading at $14.685. The IPO price was $16. Bambusa Therapeutics is a Boston-based clinical-stage biopharmaceutical company focused on developing next-generation long-acting bispecific antibody drugs for treating immune system and inflammatory diseases. These drugs can simultaneously target two disease-related biological targets, aiming to improve therapeutic efficacy, extend the duration of effect, and reduce dosing frequency for patients. The company’s lead investigational drug, BBT001, is designed to treat skin conditions such as atopic dermatitis (eczema) and chronic spontaneous urticaria. Another candidate, BBT002, mainly targets inflammatory diseases like asthma, chronic obstructive pulmonary disease, and chronic rhinosinusitis with nasal polyps. Additionally, the company is developing early-stage drugs for inflammatory bowel disease and autoimmune diseases.